News

Apnimed to Participate in the 2023 BIO International Convention

May 23, 2023

June 5-8, 2023 at the Boston Convention & Exhibit Center

Apnimed Presented Positive Phase 2b Results on AD109, an Investigational Oral Drug for Obstructive Sleep Apnea, for the First Time at ATS 2023

May 21, 2023

New MARIPOSA Study Data Showed AD109 Statistically Significantly Improved
Both Objective and Subjective Outcomes in OSA Patients

Apnimed to Present Positive Phase 2b Results on AD109, an Investigational Oral Treatment for Obstructive Sleep Apnea, at ATS 2023

May 15, 2023

– New MARIPOSA Data Showing AD109 Had Statistically Significant Improvement in Both Objective and Subjective Outcomes to Be Featured as an Oral Presentation in the Breaking News in OSA: New Approaches and New Trials Mini Symposium – Data Supporting Use of Specific...

Apnimed to Present at the 22nd Annual Needham Virtual Healthcare Conference

Apr 10, 2023

The corporate presentation will be on April 17, 2023, from 9:30 -10:10 am ET in Track 2.

Apnimed to Participate in the SVB Securities Global Biopharma Conference

Jan 25, 2023

1×1 investor meetings will take place virtually January 31- February 2, 2023

Apnimed Completes Oversubscribed $79.75 Million Series C Extension Financing to Fund Two Planned Phase 3 Trials of AD109, an Oral Medication with the Potential to Be the First Therapy for Direct Treatment of Obstructive Sleep Apnea (OSA)

Jan 3, 2023

Phase 3 Trials Expected to Begin Enrollment in Second Quarter of 2023, Subject to Discussions with the FDA

Apnimed to Present at the Stifel Healthcare Conference

Nov 8, 2022

Apnimed management will participate in the conference taking place November 15-16, 2022 in New York.

Apnimed Announces Positive Topline Results for MARIPOSA Trial of AD109, Drug Candidate with the Potential to be the First Oral Therapy for Obstructive Sleep Apnea (OSA)

Oct 17, 2022

--AD109 Achieved the Primary Endpoint of Reduced Nighttime Airway Obstruction --AD109 Significantly Improved Daytime Impairment Caused by OSA --AD109 Was Well-Tolerated CAMBRIDGE, Mass. October 17, 2022 – Apnimed, a clinical-stage pharmaceutical company focused on...

Apnimed to Participate in the 2nd Annual Needham Biotech Private Company Virtual 1×1 Forum

Oct 12, 2022

CAMBRIDGE, Mass October 12, 2022 – Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies to treat obstructive sleep apnea (OSA) and related disorders, including its lead candidate AD109, today announced that company...